Biological effects of yeast β-glucans

Agriculturae Conspectus Scientificus

Volumn 75, Issue 4, 2010, Pages 149-158

  Petravic Tominac, Vlatka ^a   Zechner Krpan, Vesna ^a   Grba, Slobodan ^a   Srecec, Siniša ^b   Panjkota Krbavcic, Ines ^a   Vidovic, Lana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Kri evci College of Agriculture   (Croatia)

Author keywords

Biological activity; Immunomodulation; Yeast; glucan

Indexed keywords

BIOACTIVITY; CANCER; CHEMICAL INDUSTRY; DISEASE TREATMENT; FOOD PRODUCTION; INHIBITION; LITERATURE REVIEW; MEDICINE; METABOLISM; MOLECULAR ANALYSIS; PHARMACEUTICAL INDUSTRY; PHYSICOCHEMICAL PROPERTY; POLYMER; WOUNDING; YEAST;

ALGAE; AVENA; BACTERIA (MICROORGANISMS); BASIDIOMYCOTA; HORDEUM; SACCHAROMYCES CEREVISIAE;

EID: 79953300758     PISSN: 13317768     EISSN: 13317776     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Adachi K., Nanba H., Kuroda H. (1987). Potentional of hostmediated antitiumor activity in mice by β-glucan obtained from Grifola fondosa (maitake). Chem Pharm Bull 34: 262-270. (Pubitemid 17021391)
2. Aguilar-Uscanga B., Francois J. M. (2003). A study of the yeast cell wall composition and structure in response to growth conditions and mode of cultivation. Lett Appl Microbiol 37: 268-274 (Pubitemid 37041227)
3. Bell S. J., Armour Forse R., Bistrian B. R. (2001). Dietary supplement and method for lowering risk of heart disease. US Patent 6,210686
4. Anonymous (2010). http://govinfo.library.unt.edu/ota/Ota 1/ DATA/1993/9313.PDF
5. Ber L. (1997). Yeast-derived β-1,3-glucan: An adjuvant concept. Am J Natural Med 4: 21-24
6. Berdal M., Hege I., Appelborn B. S., Jorunn H., Eikren B. S., Lund A., Zykova S., Busend, R. Seljelid L.-T., Jensen T. (2007). Aminated β-1,3-glucan improves wound healing in diabetic db/ db mice. Wound Rep Reg 15: 825-832 (Pubitemid 350135230)
7. Bohn J. A., BeMiller J. N. (1995). (1→3)-β-Glucans as biological response modifiers: A review of structure-functional activity relationships. Carbohyd Polym 28: 3-14
8. Browder W., Williams D., Pretus H., Olivero G., Enrichens F., Mao P., Franshello A. (1990). Benefical effect of enhanced macrophage function in trauma patients. Ann Surg 211: 605-614
9. Brown G. D., Gordon S. (2003). Fungal β-glucans and mammalian immunity. Immunity 16: 311-315
10. Brown G. D., Gordon S. (2005). Immune recognition of fungal β-glucans. Cell Microbiol 7: 471-479
11. Chichara G., Hamuro J., Meada Y. Y., Shiio T., Suga T., Takasuka N., Sasaki T. (1987). Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: An overview. Cancer Detect Prev Suppl 1: 423-444
12. Chen J., Seviour R. (2007). Review - Medicinal importance of fungal β-(1→3),(1→6)-glucans. Mycol Res 111: 635-652 (Pubitemid 47082471)
13. ™ as a feed supplement enhances macrophage respiratory burst and the growth rate of snapper (Pagrus auratus, Sparidae (Bloch and Schneider)) in winter. Fish Shellfish Immun 14: 333-345 (Pubitemid 36391653)
14. Delatte S. J., Evans J., Hebra A., Adamson W., Othersen H. B., Tagge E. P. (2001). Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pedsurg 36. 113-118 (Pubitemid 32044325)
15. Dellinger E. P., Babineau T. J., Bleicher P., Kaiser A. B., Seibert G. B., Postier R. G., Vogel, J. Norman S. B., Kaufman D., Galandiuk S., Condon R. E. (1999). Effect of PGG-glucan on the rate of serious postoperative infection or death observed aft er high-risk gastrointestinal operations. Arch Surg 134: 977-984
16. Demir G., Klein H. O., Mandal-Molinas, Tuzuner N. (2007). β-glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7: 113-116 (Pubitemid 44856386)
17. DiLuzio N. R., Williams D. L., McNamee R. B., Edwards B. F., Kaitahama A. (1979). Comparative tumor-inhibitory and antibacterial activity of soluble and particulate glucan. Int J Cancer 24: 773-779 (Pubitemid 10202851)
18. DiLuzio N. R. (1983). Immunopharmacology of glucan: A broad spectrum enhancer of host defense mechanisms, Trends Pharmacol Sci 4, 344-347
19. Donzis B. A. Method for revitalizing skin by applying topically water insoluble glucan. US Patent 5,223,491 (1993).
20. Freimund S., Sauter M., Kapelli O., Dutler H. (2003). A new nondegrading isolation process for 1,3-β-glucan of high purity from baker's yeast Saccharomyces cerevisiae. Carbohyd Polym 54: 159-171
21. Gardiner T. (2000). β-glucan biological activities: A review, Glycoscience and Nutrition, 1, 1-6
22. Gelderman K. A., Tomlinson S., Ross G. D., Gorter A. (2004). Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25: 158-154
23. Ha C. H., Lim K. H., Kim Y. T., Lim S. T., Kim C. W. (2002). Analysis of alkali-soluble glucan produced by Saccharomyces cerevisiae wild type and mutants. Appl Microbiol Biotechnol 58: 370-377 (Pubitemid 34185583)
24. Hanaue H., Tokuda Y., Machimura T., Kamijoh A., Kondo Y., Ogoshi K., Makuuchi H., Nakasaki H., Tajima T., Mitomi T. (1989). Effects of oral lentinan on T-cells subsets in peripheral venous blood. Clin Ther 11: 614-622 (Pubitemid 19247370)
25. Hayen D. G., Pollmann D. S. (1995). Animal feeds comprising yeast glucan. WHO Patent 95/04467
26. Hong F., Hansen R. D., Yan J., Allendorf D. J., Baran J. T., Ostroff G. R., Ross G. D. (2003). Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63: 9023-9031 (Pubitemid 38064084)
27. Hong F., Yan J., Baran J. T., Allendorf D. J., Hansen R. D., Ostroff G. R., Xing P. X., Cheung N.-K. V., Ross G. D. (2004). Mechanism by whichorally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173: 797-806 (Pubitemid 38924254)
28. Hromádková Z., Ebringerová A., Sasinková V., Šandulá J., Hríbalová V., Omelková J. (2003). Influence of the drying method on the physical properties and immunomodulatory activity of the particulate (1→3)-β-D-glucan from Saccharomyces cerevisiae. Carbohyd Polym 51: 9-15
29. Hunter K. W., Gault R. A., Berner M. D. (2002). Preparation of microparticulate β-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett Appl Microbiol 35: 267-271 (Pubitemid 35205345)
30. Jamas S., Ostroff G. R., Easson Jr. D. D. (1991). Glucan drug delivery system and adjuvant. US Patent 5,032,401
31. Jordan F. M, Hunter K. W., R. Gault R. (2002). Method for preparing small particle size glucan in a dry material. US Patent 6,476,004
32. Kath F., Kulicke W. M. (1999). Mild enzymatic isolation of mannan and glucan from yeast Saccharomyces cerevisiae. Angew Makromol Chem 268: 59-68
33. Keller T. (2000). Compounding with β-1,3-D-glucan. International Journal of Pharmaceutical Compounding 4: 342-345
34. Kedzierska A. (2007). (1→3)-β-D-glucan - A new marker for the early serodiagnosis of deep-seated fungal infections in humans. Pol J Microbiol 56: 3-9 (Pubitemid 46814164)
35. Keogh G. F., Cooper G. J., Mulvey, T. B., McArdle B. H., Coles, G. D., Monro J. A., Poppitt S. D. (2003). Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr 78: 711-718 (Pubitemid 39663488)
36. Kernodle D., Gates H., Kaiser A. B. (1998). Prophylactic antiinfective activity of poly-[1-6]-β-D-glucopyranosyl-[1-3]-β-Dglucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother 42: 545-549 (Pubitemid 28114806)
37. Klis F. M., Caro L. H., Vossen J. H., Kapteyn J. C., Ram A. F., Montijn R. C., Van Berkel M. A., Van den Ende H. (1997). Identification and characterization of a major building block in the cell wall of Saccharomyces cerevisiae. Biochem Soc Trans 25: 856-860
38. Kirmaz C., Bayrak P., Yilmaz O., Yuksel H. (2005). Effects of glucan treatment on the Th 1/Th 2 balance in patients with allergic rhinitis: A double-blind placebo-controlled study. Eur. Cytokine Netw 16: 128-134 (Pubitemid 46638761)
39. Kogan G., Staško A., Bauerova K., Polovka M., Soltes L., Brezova V., Navarova J., Mihalova D. (2005). Antioxidant properties of yeast (1,3)-β-D-glucan studies by electron paramagnetyc resonance spectroscopy and its activity in the adjuvant arthritis. Carbohyd Polym 61: 18-28 (Pubitemid 40774009)
40. Kougias P., Wei D., Rice P. J., Ensley H. E., Kalbfleisch , J. H., Williams D. L., Browder I. W. (2001). Normal human fibroblasts express pattern recognition receptors for fungal (1→3)-β-Dglucans. Infect Immun 69: 3933-3938 (Pubitemid 32493315)
41. Kulicke M. W., Lettau A. I., Thielking H. (1997). Correlation between immunological activity, molar mass and molecular structure of a diff erent (1→3)-β-D-glucans. Carbohyd Res 297: 135-139
42. 1
43. Laroche C., Michaud P. H. (2007). New developments and prospective applications for β-(1,3)-glucans. Recent Pat on Biotechnol 1: 59-74
44. LeBlanc B. W., Albina J. E., Reichner J. S. (2006). The effect of PGG- β-glucan on neutrophill chemotaxis in vivo. J Leukoc Biol 79: 667-675 (Pubitemid 44835599)
45. Lee J. N., Lee D. Y., Ji I. H., Kim G. E., Kim H. N., Sohn J., Kim S., Kim C. W. (2001). Purification of soluble β-glucan with immune-enhancing activity from the cell wall of yeast. Biosci Biotechnol Biochem 65: 837-841 (Pubitemid 33614169)
46. Lee S. B., Jeon H. W., Lee Y. W., Song K. W., Park M. H., Nam Y. S., Ahn H. C. (2003). Bio-artificial skin composed of gelatin and (1→3),(1→6)- β-glucan. Biomaterials 24. 2503-2511 (Pubitemid 36407667)
47. Li B., Allendorf D. J., Hansen R., Marroquin J., Ding C., Cramer D. E., Yan J. (2006). Yeast β-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complements receptor 3-Sykphosphatidylinositol 3-kinase pathway. J Immunology 177: 1661-1669 (Pubitemid 44092502)
48. Liang J., Melican D., Cafro L., Palace G., Fisette L., Armstrong R., Patchen M. L. (1998). Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 20: 595-614 (Pubitemid 28535144)
49. Lipke N. P., Ovalle R. (1998) Cell wall architecture in yeast: Mew structure and new challenges (minireview). J Bacteriol 180: 3735-3740 (Pubitemid 28361564)
50. Lloyd L. L., Kennedy J. F., Methacanon P., Paterson M., Knill C. J. (1998). Carbohydrate polymers as wound management aids. Carbohyd Polym 37: 315-322 (Pubitemid 128426051)
51. Machova E., Kogan G., Alfoldi J., Šoltes L., Šandula T. (1995). Enzymatic and ultrasonic depolymerization of carboxymethylated β-1,3-D-glucan derived from Saccharomyces cerevisiae. J Appl Polym Sci 55: 699-704
52. Mantovani M. S., Bellini M. F., Angeli J. P. F., Oliveira R. J., Silva A. F., Ribeiro L. R. (2008). β-Glucans in promoting health: Prevention against mutation and cancer. Mutat Res 658: 154-161 (Pubitemid 351662709)
53. Mason R. (2001). What is beta-glucan? In:Safe goods. New Century Publishing 2000, pp 4-36. Printed in USA: Http://www. youngagain.org/book-what- is-beta-glucan.htm
54. Morikawa K., Takeda R., Yamazaki M., Mizuno D. (1985). Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear β-1,3-D-glucan and other immunomodulators in murine cells. Cancer Res 45: 1496-1501 (Pubitemid 15079093)
55. Mueller A., Raptis J., Rice P. J., Kalbfleisch J. H., Stout R. D., Ensley H. E., Browder W., Williams D. L. (2000). The influence of glucan polymer structure and solution conformation on binding to (1→3)-β-D-glucan receptors in a human monocyte-like cell line. Glycobiology 10: 339-346 (Pubitemid 30184604)
56. Nanba H., Kuroda H. (1987). Potentiating effect of β-glucan from Cochliobolus miyabeanus on host-mediated antitumor activity in mice. Chem Pharm Bull 35: 1289-1294
57. Naumann E., Van Rees A. B., Onning G., Oste R., Wydra M., Mensink R. P. (2006). β-glucan incorporation into a fruit drink effectively lowers serum LDL-cholesterol. Amer J Clin Nutrit 83: 601-605 (Pubitemid 44699205)
58. Nguyen H. T., Fleet G. H., Rogers L. P. (1998). Composition of the cell walls of several yeast species. Appl Microbiol Biotechnol 50: 206-212 (Pubitemid 28414542)
59. Nicolosi R., Bell S. J., Bistrian B. R., Greenberg I., Forse R. A., Blackburn G. L. (1999). Plasma lipid changes aft er supplementations with β-glucan fiber from yeast. Am J Clin Nutr 70: 208-212 (Pubitemid 29347565)
60. Nikl H. L., Allbright J. L. (1993). Composition and method to enhance the efficacy of a fish vaccine and to stimulate the imunne system of fish. US Patent 5,189,028
61. Novak M., Vetvicka V. (2008). Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action. J Immunotox 5: 47-57 (Pubitemid 351431257)
62. Ohno N., Suzuki T., Saito K., Yadomae T. (1990). Enhancement of clot formation in human plasma by β-glucans. J Pharmacobio- Dyn 13: 525-532 (Pubitemid 20341335)
63. Oliveira R. J., Matuo R., Silva A. F., Matiazi H. J., Mantovani M. S., Ribeiro L. R. (2006). Protective effect of β-glucan extracted from Saccharomyces cerevisiae, against DNA damage and cytotoxicity in wild-type (k1) and repair-deficient (xrs5) CHO cells. Toxicol In Vitro 21: 41-52 (Pubitemid 44855512)
64. Onderdonk A. B., Cisneros R. L., Hinkson P., Ostroff G. (1992). Anti-infective effect of poly-β-6-glucotriosyl-β -3-glucopyranose glucan in vivo. Infect Immun 60: 1642-1647
65. Ostroff G. R., Ross G. D. (2004). Methods of using β-glucan as a radioprotective agent. WO/2004/014320
66. Osumi M. (1998). The ultrastructure of yeast: Cell wall structure and formation. Micron 29: 207-234
67. Patchen M. L., D'Alesandro M. M., Brook I., Blakely W. F., MacVittie M. J. (1987). Glucan: Mechanisms involved in its "radioprotective" effect. J Leuc Biol 42: 95-105 (Pubitemid 17099551)
68. Patchen M. L., MacVittie T. J. (1987). Comparative effects of soluble and particulate glucans on survival in irradiated mice. J Biol Resp Modif 5: 45-60 (Pubitemid 16167629)
69. Pillai R., Redmond M., J. Röding J. (2005). Anti-wrinkle therapy: Significant new fi ndings in the non-invasive cosmetic treatment of skin wrinkles with β-glucan. IFSCC Magazine 8: 17-21
70. Portera C. A., Love E. J., Memore L., Zhang L., Millre A., Browder W., Williams D. L. (1997). Effect of macrophage stimulation on collagen biosynthesis in healing wound. Am Surg 63: 125-131 (Pubitemid 27057062)
71. Rice P. J., Kelley J. L., Kogan G., Ensley H. E., Kalbfleisch J. H., Browder I. W., Williams D. L. (2002). Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-glucans. J Leukocyte Biol 72: 140-146
72. Rice P. J, Adams E. L., Ozment-Skelton T., Gonzales A. J., Goldman M. P., Lockhart B. E., Barker L. A., Breuel K. F., DePonti V. K., Klabfleisch J. H., Ensley H. E., Brown G. D., Gordon S., Williams D. L. (2005). Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 314: 1079-86 (Pubitemid 41205971)
73. Ross G. D., Vetvicka V., Yan J., Xia Y., Vetvickova J. (1999). Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 42: 61-74 (Pubitemid 29322289)
74. Ross J. S., Schenkein D. P., Pietrusko R., Rolfe M., Linette G. P., Stec J., Stagliano N. E., Ginsburg G. S:, Symmans W. F., Pusztai L., Hortobagyi G. N. (2004). Targeted therapies for cancer. Am J Clin Pathol 122: 598-609
75. Ruiz-Herrera J. (1991). Biosynthesis of β-glucans in fungi. Antonie Van Leeuwenhoek 60: 72-81
76. Salvador C., Li B., Hansen R:, Cramer D. E., Kong M., Yan J. (2008). Yeast derived β-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograf models. Clin Cancer Res 14: 1239-1247 (Pubitemid 351302573)
77. Steriti R. (2007). Beta-glucans for cardiovascular support. Dynamic Chiropractis 7: 1-6
78. Stone B. A., Clarke A. E. (1992). Chemistry and Biology of (1→3)-β-glucans, La Trobe University Press, Australia
79. Šandula J., Kogan G., Kacurakova M., Machova E. (1999). Microbial (1→3)-β-D-glucans, their preparation, physico-chemical characterization and immunomodulatory activity. Carbohyd Polym 38: 247-253
80. Takahashi T., Yamazaki Y., Kato K. (1978). β-1,3-derivatives. US Patent 4,075,405
81. Thompson I. M., Spence C. R., Lamm D. L., DiLuzio N. R. (1987). Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. Am J Med Sci 294: 294-300 (Pubitemid 17167008)
82. Teparic R., Mrša V. (1997). Purification of yeast periplasmic proteins using protein adsorption to glucan. Food Technol. Biotechnol 35: 29-32 (Pubitemid 127705161)
83. Tokunaka K., Ohno N., Adachi Y., Yadomae T. (2000). Immunopharmacological and immunotoxicological activities of a water soluble β-(1→3)-glucan, CSBG from Candida spp. Int J Immunopharmacol 22: 383-394 (Pubitemid 30116721)
84. Tzianabos A. O., Cisneros R. L. (1996). Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann N.Y. Acad Sci 797: 285-287 (Pubitemid 27055611)
85. Tzianabos A. O., Gibson III F. C., Cisneros R. L., Kasper D. L. (1998). Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. J Infect Dis 178: 200-206 (Pubitemid 28328094)
86. Tzianabos A. O. (2000). Review-Polysaccharide immunomodulators as therapeutic agents: Structural aspects and biologic function. Clin Microbiol Rev 13: 523-534
87. Ueno H. (2000). β-1,3-D-Glucan, its immune effect and its clinical use. Jap J Soc Term Syst Dis 6 151-154
88. Vaidya B. K., Singhal R. S. (2008). Use of insoluble yeast β-glucan as a support for immobilization of Candida rugosa lipase. Colloid Surface B 61: 101-105 (Pubitemid 350296854)
89. Vetvicka V., Thornton B. P., Ross G. D. (1996). Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98: 50-61 (Pubitemid 26243820)
90. Vetvicka V. (2001). β-Glucans as imunomodulators. JANA 3: 31-34
91. Vetvicka V., Terayama K., Mandeville R., Brousseau P., Kournikakis B., Ostroff G. (2002). Pilot study: Orally-administered yeast β-1,3-glucan prophylactically protects against antrax infection and cancer in mice. JANA 5: 1-6
92. Vetvicka V., Yvin J. C. (2004). Effects of marine β-1,3-glucan on immune reactions. Int Immunopharmacol 4. 721-730 (Pubitemid 38595529)
93. Vetvicka V., Vetvickova J. (2007). An evaluation of the immunological activities of commercially available β-1,3- glucans. JANA 10: 25-31
94. Vetvicka V, Dvorak B., Vetvickova J., Richter J., Krizan J., Sima P., Yvin J.C. (2007). Orally administered marine (1→3)-β-D-glucan phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol 40: 291-298
95. Vetvicka V., Volny T., Saraswat-Ohri S., Vashishta A., Vancikova Z., Vetvickova J. (2007). Glucan and resveratrol complex - possible synergistic effects on immune system, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 151 (2007) 41-46.
96. Volman, J. J., Ramakers, J. D., Plat J. (2008). Dietary modulation of immune function by β-glucans. Physiology and Behavior 94: 276-284 (Pubitemid 351615420)
97. Wagner H., Stuppner H., Schafer W., Zenk M. (1988). Immunologically active polysaccharides of Echinacea purpura cell cultures. Phytochemistry 27: 119-126
98. Wakshull E., Brunke R. D., Lindermuth J., Fisette L., Nathans R. S., Crowley J. J., Tufts J. C., Zimmerman J., Mackin W., Adams D. S. (1999). PGG-glucan, a soluble β-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity and activates an NF-kappa B-like factor in human PMN: Evidence for glycosphingolipid β-(1,3)-glucan receptor. Immunopharmacology 41: 89-107 (Pubitemid 29099822)
99. Weitberg A. B. (2008). A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. Journal of Experimental and Clinical Cancer Research 27: 40-44
100. Williams D. L., Mcnamee R. B., Jones E. L., Pretus H. A., Ensley H. E., Browder I. W., DiLuzio N. R. (1991). A method for the solubilization of a (1→3)-β-D-glucan isolated from Saccharomyces cerevisiae. Carbohyd Res 219: 203-214
101. Wei D., Zhang L., Williams D. L., Browder I. W. (2002). Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen 10: 161-168 (Pubitemid 34760894)
102. Wheatcroft R., Kulandai J., Gilbert R. W., Sime K. J., Smith C. G., Langeris W. H. (2002). Production of β-glucan-mannan preparations by autolysis of cells under certain pH, temperature and time conditions. US Patent 6,444,448
103. Zechner-Krpan V., Petravic-Tominac V., Panjkota-Krbavcic I., Grba S., Berkovic K. (2009) Potential application of yeast β-glucans in food industry. Agric Conspec Sci 74(4):277-282
104. Zekovic D. B, Kwiatkowski S., Vrvic M. V., Jakovljevic D., Moran C. A. (2005). Natural and modified (1 3)-β-D-glucans in health promotion and disease allevation. Crit Rev Biotechnol 25: 205-230 (Pubitemid 41759220)